Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:ABT
Abbott Labs (ABT)
88.59
+0.18 (0.20%)
as of Jun 18, 2026, 11:52:08 pm Market Open.
234 watching
Financials 
Technical Analysis 0
TOP PICK
Believes healthcare will hold up well in recessionary periods
Has averaged 16% returns the last 5 years.
Consistent earnings growth and profit margins.
Large business with diverse revenue model.
Has increased dividend the past 50 years.
Brianne GardnerOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Oct 13/21, Down 7%) They made Covid test kits and generated $15 billion. They also have medical devices, a division that is improving, and pharmaceuticals that sell generic drugs to emerging markets, and infant formulas, but that ran into troubles. She likes their diversity and has many drugs in the pipeline. It has raised its dividend in the past 50 years. Happy to hold it.
Christine PooleOwned
biotechnologypharmaceutical
BUY
Allan Tong’s Discover Picks Abbott stocks trade at a 25.18x PE at a low 0.74 beta, and pays a 1.73% dividend. Its valuation is significantly lower than peers Stryker (36.4x) and Becton Dickinson (37.3x) while its profit margin scores much higher at 17.35% vs. 11.56% and 9.59% respectively. ROI is also comparably higher while Abbott stock’s 1.73% divvy is in-line with this sector (and safe at a 42.17% payout ratio). Back to earnings: Abbott stocks have beaten their last four quarters handily. Read Our 3 defensive healthcare stocks picks for our full analysis.
Stockchase DiscoverOwned
biotechnologypharmaceutical
BUY
Their last quarter was very good, beating the street, but shares have been down. Part of their growth came from Covid testing, which grew well. Their medical devices business was up 8%, though the last two years halted elective surgeries. This hurt ABT but will improve (like JNJ did) because there's a huge backlog of surgeries. Earnings will grow for several years. He owns Stryker, but likes Abbott a lot.
biotechnologypharmaceutical
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
(A Top Pick May 31/22, Down 10.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $105. To remain disciplined we recommend covering the position at this time. This will result in a net investment loss of 12%, when combined with previous buy recommendations.
biotechnologypharmaceutical
Premium contentTOP PICK
Abbott has handily beaten its last four quarters, pays a steady 1.61% dividend and trades at 27x. That valuation is a little higher than AbbVie's 21.34x and Johnson & Johnson's 24x though well below Eli Lilly's 46x. Stockchaser Mike O'Reilly trusts Abbott's management, performance and prospects.
biotechnologypharmaceutical
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly ABT was embroiled in a whistleblower complaint that led to shutdown of a key baby formula plant. Now that the company has effectively been cleared of wrongdoing, the plant will be reopening and we again reiterate ABT as a TOP PICK. Recently reported earnings beat expectations and support at ROE of 28%. The have aggressively bought back shares and are retiring debt early. They are a Dividend Aristocrat, raising dividends for 50 consecutive years. We continue to recommend a stop loss at $105, looking to achieve $143 -- upside potential over 20%. Yield 1.6% (Analysts’ price target is $140.17)
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 18/21, Down 2%) A diversified healthcare company including diagnostics, nutrtiion, and generic drugs. They made many Covid testing kits, so they benefitted from the pandemic. Shares got hit as the pandemic waned. Still, they've made a lot of money, so they can use that cash flow to buy other companies. The medical devices business will ramp up as surgeries do. Last quarter, their infant formula controversy led them closing their plants; later, ABT was cleared of wrongdoing, so this business will ramp back up. They increase their dividend each year. Pays 2% yield now.
Christine PooleOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jun 08/21, Up 11%) Still likes. Now above his buy price of $110. Watch and wait for a pullback, as there will be volatility with diagnostics testing winding off.
Chris BlumasOwned
biotechnologypharmaceutical
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly ABT has benefited from COVID-19 testing worldwide, is the second largest cardiologic technology company in the world, and is a large player in the continuous glucose monitoring market for diabetes. It trades at 30x earnings, compared to peers at 23x; however, forward earnings support a 23x valuation. It is a little expensive at over 5x book value. It pays a small dividend (that has been growing for 50 years consecutively), backed by a payout ratio under 50% of cash flow. Its most recent earnings beat expectations by 11% and support a strong 27% ROE. It has been building cash reserves while paying down debt. We would recommend setting a stop loss at $105, looking to achieve $143 -- 18% upside potential. Yield 1.59% (Analysts’ price target is $142.88)
biotechnologypharmaceutical
TOP PICK
Has owned this for years, but is buying at current prices. They make the Covid-testing kits, totalling $10 billion revenues. Demand here will likely soften. The stock price is flat over the year, despite those revenues, but at least the cash flow from the testing can lead to more products and acquisition. They forecast they can grow revenues around 9%. Attractive stock price now. Diagnostic and medical devices are good business. Pharmas are selling to emerging markets. Their glucose monitoring system is doing well. Their heart products are a new source of growth. Attractive PE. (Analysts’ price target is $139.72)
Christine PooleOwned
biotechnologypharmaceutical
BUY
Has owned this many years. It's sensitive to the Covid testing environment, like now during Omicron. So, it's has a nice run from this increasing demand. But the market always looks forward, so Abbott doesn't enjoy that testing rise. They report later this month. She is waiting for a slightly lower entry point. Nobody knows what will happen with Covid, but the pandemic has given them a nice cash cushion while medical devices and diagonistics divisions are doing well and will grow, she think around 8-12%. She likes this long term.
Christine PooleOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
